Total Payments
$16,532
2024 Payments
$13,780
Companies
32
Transactions
169
Medicare Patients
265
Medicare Billing
$17,701
Payment Breakdown by Category
Research$13,801 (83.5%)
Food & Beverage$2,679 (16.2%)
Gifts$38.72 (0.2%)
Education$14.31 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,801 | 2 | 83.5% |
| Food and Beverage | $2,679 | 165 | 16.2% |
| Gift | $38.72 | 1 | 0.2% |
| Education | $14.31 | 1 | 0.1% |
Payments by Type
Research
$13,801
2 transactions
General
$2,732
167 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $13,801 | 2 | $0 (2024) |
| AbbVie Inc. | $870.71 | 57 | $0 (2023) |
| Astellas Pharma US Inc | $284.03 | 14 | $0 (2024) |
| Avion Pharmaceuticals | $205.11 | 15 | $0 (2023) |
| MAYNE PHARMA COMMERCIAL LLC | $138.11 | 13 | $0 (2024) |
| Medical Device Business Services, Inc. | $124.92 | 1 | $0 (2017) |
| PFIZER INC. | $115.62 | 10 | $0 (2023) |
| TherapeuticsMD, Inc. | $110.63 | 7 | $0 (2022) |
| Organon LLC | $101.67 | 6 | $0 (2023) |
| Novo Nordisk Inc | $87.29 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,780 | 11 | Eli Lilly and Company ($13,631) |
| 2023 | $703.36 | 38 | Eli Lilly and Company ($169.54) |
| 2022 | $419.45 | 29 | ABBVIE INC. ($122.99) |
| 2021 | $722.02 | 39 | AbbVie Inc. ($406.38) |
| 2020 | $321.80 | 20 | AbbVie Inc. ($129.63) |
| 2019 | $205.50 | 13 | AbbVie, Inc. ($82.92) |
| 2018 | $28.05 | 2 | Duchesnay USA Incorporated ($15.14) |
| 2017 | $351.90 | 17 | Medical Device Business Services, Inc. ($124.92) |
All Payment Transactions
169 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $13,631.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | ||||||
| 07/23/2024 | MILLICENT US INC | FEMRING (Drug), INTRAROSA | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: TREAT SYMPTOMS OF MENOPAUSE | ||||||
| 07/09/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Biological | ||||||
| 05/13/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: HORMONE THERAPY | ||||||
| 04/22/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Biological | ||||||
| 03/07/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Biological | ||||||
| 02/23/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $9.00 | General |
| 02/23/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $0.82 | General |
| 02/20/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: Biological | ||||||
| 01/25/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $19.10 | General |
| 01/15/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $5.57 | General |
| 12/10/2023 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: CONTRACEPTIVE | ||||||
| 12/08/2023 | AbbVie Inc. | ORILISSA (Drug), LO LOESTRIN FE | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: WOMENS HEALTH | ||||||
| 12/07/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Biological | ||||||
| 11/21/2023 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/06/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: Biological | ||||||
| 11/02/2023 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/02/2023 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $0.11 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/01/2023 | Organon LLC | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: ETONOGESTREL | ||||||
| 10/20/2023 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: CONTRACEPTIVE | ||||||
| 10/10/2023 | PFIZER INC. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $3.52 | General |
| Category: GENITOURINARY (SEXUAL HEALTH);WOMENS HEALTH | ||||||
| 10/05/2023 | AbbVie Inc. | ORILISSA (Drug), LO LOESTRIN FE | Food and Beverage | In-kind items and services | $10.17 | General |
| Category: WOMENS HEALTH | ||||||
| 10/03/2023 | MILLICENT US INC | FEMRING (Drug), INTRAROSA | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: TREAT SYMPTOMS OF MENOPAUSE | ||||||
| 09/26/2023 | AbbVie Inc. | LILETTA (Drug) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: WOMENS HEALTH | ||||||
| 09/21/2023 | Eli Lilly and Company | — | — | In-kind items and services | $169.54 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | Eli Lilly and Company | $13,631 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $169.54 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 45 | 51 | $4,170 | $1,907 |
| 2022 | 3 | 61 | 81 | $7,035 | $3,883 |
| 2021 | 4 | 60 | 83 | $9,250 | $4,929 |
| 2020 | 5 | 99 | 129 | $13,966 | $6,982 |
Total Patients
265
Total Services
344
Medicare Billing
$17,701
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 19 | $2,090 | $695.96 | 33.3% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2023 | 16 | 16 | $640.00 | $627.20 | 98.0% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 16 | 16 | $1,440 | $584.16 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 39 | $4,255 | $2,252 | 52.9% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2022 | 21 | 21 | $924.00 | $836.39 | 90.5% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2022 | 21 | 21 | $1,856 | $794.60 | 42.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 46 | $5,460 | $2,946 | 54.0% |
| 76830 | Ultrasound pelvis through vagina | Office | 2021 | 11 | 12 | $2,290 | $1,008 | 44.0% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 13 | 13 | $874.00 | $488.93 | 55.9% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2021 | 12 | 12 | $626.00 | $485.40 | 77.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 58 | $7,215 | $3,253 | 45.1% |
| 76830 | Ultrasound pelvis through vagina | Office | 2020 | 13 | 13 | $2,210 | $1,180 | 53.4% |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | Office | 2020 | 23 | 23 | $1,150 | $922.95 | 80.3% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2020 | 23 | 23 | $1,195 | $889.01 | 74.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 12 | 12 | $2,196 | $737.36 | 33.6% |
About Dr. Scott Striplin, M.D
Dr. Scott Striplin, M.D is a Obstetrics & Gynecology healthcare provider based in Covington, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1205830775.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Striplin, M.D has received a total of $16,532 in payments from pharmaceutical and medical device companies, with $13,780 received in 2024. These payments were reported across 169 transactions from 32 companies. The most common payment nature is "" ($13,801).
As a Medicare-enrolled provider, Striplin has provided services to 265 Medicare beneficiaries, totaling 344 services with total Medicare billing of $17,701. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Location Covington, LA
- Active Since 06/11/2005
- Last Updated 01/06/2021
- Taxonomy Code 207V00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1205830775
Products in Payments
- ORILISSA (Drug) $259.91
- LO LOESTRIN FE (Drug) $234.51
- LILETTA (Drug) $224.67
- Balcoltra (Drug) $184.09
- Veozah (Drug) $180.10
- NEXPLANON (Drug) $149.05
- SURGICEL Family of Absorbable Hemostats (Device) $124.92
- Myrbetriq (Drug) $103.93
- NEXTSTELLIS (Drug) $103.62
- OVA1 (Device) $85.39
- Orilissa (Drug) $82.92
- PREMARIN (Drug) $69.64
- ANNOVERA (Drug) $62.97
- Saxenda (Drug) $59.62
- MYFEMBREE (Drug) $52.43
- Osphena (Drug) $51.26
- ORIAHNN (Drug) $39.28
- ESTROGEL (Drug) $38.72
- BIJUVA (Drug) $36.19
- FEMRING (Drug) $35.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Covington
Dr. Zsakeba Henderson, M.d, M.D
Obstetrics & Gynecology — Payments: $13,992
Obstetrics & Gynecology $13,992
Sherley Samuels, M.d, M.D
Obstetrics & Gynecology — Payments: $9,219
Obstetrics & Gynecology $9,219
Dr. Jamie Hymel, M.d, M.D
Obstetrics & Gynecology — Payments: $9,000
Obstetrics & Gynecology $9,000
Julie Landry, Md, MD
Obstetrics & Gynecology — Payments: $8,952
Obstetrics & Gynecology $8,952
Dr. James Rice, M.d, M.D
Obstetrics & Gynecology — Payments: $7,494
Obstetrics & Gynecology $7,494
Mrs. Kelly Brewster, Whnp, WHNP
Obstetrics & Gynecology — Payments: $5,743
Obstetrics & Gynecology $5,743